Bemfivastatin hemicalcium

Modify Date: 2024-03-14 17:21:43

Bemfivastatin hemicalcium structure	Common Name	Bemfivastatin hemicalcium
	CAS Number	805241-64-9	Molecular Weight	607.74
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₄H₃₇FN₂O_6.1/₂Ca	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bemfivastatin hemicalcium

Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.

Name	Bemfivastatin hemicalcium

Description	Bemfivastatin (PPD 10558) hemicalcium is an orally active lipid-lowering agent and HMG-CoA reductase inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extracts. Bemfivastatin hemicalcium has no-observed adverse effect levels (NOAEL) with dosages of ≥320 mg/kg/d (rat developmental toxicity), ≥12.5 mg/kg/d (rabbit maternal toxicity), ≥25 mg/kg/d (rabbit developmental toxicity), respectively. Bemfivastatin hemicalcium can be used in the study of statin-related hypercholesterolemic myalgia in statin-intolerant patients.
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> HMG-CoA Reductase (HMGCR) Research Areas >> Metabolic Disease
References	[1]. Faqi AS, et al. Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95(1):23-37.

Molecular Formula	C₃₄H₃₇FN₂O_6.1/₂Ca
Molecular Weight	607.74

Bemfivastatin hemicalcium

Use of Bemfivastatin hemicalcium

Names

Bemfivastatin hemicalcium Biological Activity

Chemical & Physical Properties